计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C650431-5mg |
5mg |
期货 ![]() |
| |
| C650431-10mg |
10mg |
期货 ![]() |
| |
| C650431-50mg |
50mg |
期货 ![]() |
| |
| C650431-100mg |
100mg |
期货 ![]() |
|
| 别名 | CK2/ERK8 合一 |
|---|---|
| 英文别名 | GTPL8140 | TMCB | CK2/ERK8-IN-1 | Casein Kinase II Inhibitor VI | 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid | [4,5,6,7-Tetrabromo-2-(Dimethylamino)-1h-Benzimidazol-1-Yl]acetic Acid | 2-(4,5,6,7-Tetrabromo-2-(dimethylamino)-1H-be |
| 规格或纯度 | ≥99% |
| 英文名称 | CK2/ERK8-IN-1 |
| 生化机理 | CK2/ERK8-IN-1 是酪蛋白激酶 2(CK2)(K i 为 0.25 µM)和 ERK8(MAPK15、ERK7)的双重抑制剂,IC 50 s 为 0.50 μM。CK2/ERK8-IN-1 还能与 PIM1、HIPK2(同源染色体互作蛋白激酶 2)和 DYRK1A 结合,其 K i s 分别为 8.65 µM、15.25 µM、a.2 µM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激活剂 |
| 产品介绍 |
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy In Vitro CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Jurkat cells Concentration: 0-50 µM Incubation Time: 24 hours Result: Inhibited cell growth in a dose-dependent manner. Form:Solid IC50& Target:CK2 0.5 μM (IC 50 ) CK2 0.25 μM (Ki) ERK8 0.5 μM (IC 50 ) PIM1 8.65 μM (Ki) HIPK2 15.25 μM (Ki) DYRK1A 11.9 μM (Ki) Apoptosis |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid |
| INCHI | 1S/C11H9Br4N3O2/c1-17(2)11-16-9-7(14)5(12)6(13)8(15)10(9)18(11)3-4(19)20/h3H2,1-2H3,(H,19,20) |
| InChi Key | PHAOTASRLQMKBE-UHFFFAOYSA-N |
| Smiles | CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br |
| Isomeric SMILES | CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br |
| 关联CAS | 905105-89-7 |
| PubChem CID | 46943415 |
| MeSH Entry Terms | (4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo(d)imidazol-1-yl)acetic acid;4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid |
| 分子量 | 534.82 |
| 溶解性 | DMSO : 16.67 mg/mL (31.17 mM; Need ultrasonic) |
|---|---|
| 分子量 | 534.820 g/mol |
| XLogP3 | 4.400 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 534.739 Da |
| 单同位素质量Monoisotopic Mass | 530.743 Da |
| 拓扑极表面积Topological Polar Surface Area | 58.400 Ų |
| 重原子数Heavy Atom Count | 20 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 387.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |